絞り込み

16506

広告

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

著者 Horn L , Gettinger S , Camidge DR , Smit EF , Janjigian YY , Miller VA , Pao W , Freiwald M , Fan J , Wang B , Chand VK , Groen HJM
Lung Cancer.2017 Nov ; 113():51-58.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (41view , 0users)

Full Text Sources

Medical

Miscellaneous

In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) with acquired resistance to erlotinib or gefitinib. Here, a separate cohort exploring afatinib plus cetuximab after progression on afatinib is reported.
PMID: 29110849 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード